Synthesis of p ‐Coumarates With Potential Anti‐Alzheimer's Action: Enzyme Inhibition and In Silico Studies

Read full text Summarise with VIRAT
Authors: Susiany Pereira Lopes, Jeremias Emídio, Allana Brunna Sucupira Duarte, İlkay Erdoğan Orhan, Fatma Sezer Şenol, Ramin Ekhteiari Salmas, Damião Pergentino de Sousa
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Alzheimer's disease (AD) is a fatal neurodegenerative disorder that affects cognition, memory, and behavior. Such a disease is considered the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, cholinesterase inhibitors are used to reduce the symptoms and rate of progression of this disease. Thus, the present study evaluated the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities of a set of 22 p ‐coumarate derivatives using the spectrophotometric method. The inhibitory activity of the compounds against AChE and BChE was measured using the adapted Ellman spectrophotometric method; the reported inhibition percentages were determined at a final concentration of 100 µM. The structures of the synthesized compounds were characterized by FTIR, 1 H‐NMR, 13 C‐NMR, and HRMS spectroscopy. Among the compounds tested, three showed moderate inhibitory activity against AChE and good activity against BChE: ( E )‐4‐chlorobenzyl 3‐(4‐hydroxyphenyl)acrylate ( 14 ) (56.36%; 75.17%), ( E )‐4‐bromobenzyl 3‐(4‐hydroxyphenyl)acrylate ( 15 ) (61.11%; 76.09%), and ( E )‐naphthalene 3‐(4‐hydroxyphenyl)acrylate ( 18 ) (59.18%; 65.39%), respectively. Compound 15 had an IC 50 of 22.22 ±1.50 mM against BChE, which is notably better than galantamine's BChE inhibition. The in silico analysis suggested that compounds 14 , 15 , and 18 interact with AChE and BChE. Thus, p ‐coumaric acid derivatives represent promising prototypes for the search for new drug candidates for the treatment of AD.

Fields of Study & Subjects

Cholinesterase and Neurodegenerative Diseases Heterocyclic Compound Synthesis and Bioactivity Alzheimer's disease research and treatments

Publication details

Journal / source
Chemistry & Biodiversity
Volume
23
Issue
4
Pages
e03857–e03857
Publication date
1 April 2026
Language
EN